Print this page    •   Back to Web version of article

In the Dog House: Chiron

January 2003

In the Dog House: Chiron Chiron Corporation, maker of interleukin-2 (IL-2), the most promising immunotherapy for HIV, for dropping the most important study of the drug without completing it. The company has given various excuses and reasons, but the bottom line is money and an intention to become less involved in HIV. Negotiations are underway to revive a streamlined version of the study, but Chiron continues to offer less financial support than needed.

Want to tell them how you feel about this? Write or email:
Sean P. Lance, CEO
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608-2916
sean_lance@chiron.com


Back to the Project Inform Perspective January 2003 contents page.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5586.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.